TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence to long-term exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete response rate for high-risk HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression rate of persistent oncogenic HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of necrotizing enterocolitis (NEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of NEC requiring surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Right parietal cortex volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 50% or greater NRS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% or greater ONDI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonfatal cardiovascular disease event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in compliance with physiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in sleep patterns
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: time to occurrence of fungal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Urine potassium reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine sodium reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine magnesium reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event-related discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain after six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of HL2351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean apparent clearance of HL2351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of HL2351 after administration
Endpoint domain: Adverse events/effects
Primary endpoint: aApoA-I antibodies production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FORT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bone level to the implant-abutment interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RIFLE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total ischemic time per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischemic time per episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum depth of ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attention improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue blood flow at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceptions of social constraints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fidelity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preparedness to provide care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-efficacy in dealing with caregiving situations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postprandial endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extrinsic stain removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AIDS-defining illnesses
Endpoint domain: Mortality/survival
Primary endpoint: Maximum concentration of 21-desacetyldeflazacort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average area under the curve of 21-desacetyldeflazacort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of 21-desacetyldeflazacort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in S100b levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in NLR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of postsurgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of gait capabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average time of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vitreous haze score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-frequency HRV (HF HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low-frequency HRV (LF HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LF:HF ratio of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average MTR from brain tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in HAM-D-17 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate as indicated by Clinical Global Impressions-Improvement score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D-17 score ≤ 10 at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean A1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects achieving A1C <7.0% without confirmed hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean 2-h postdinner plasma glucose increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HRQOL physical component summary change scores (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive cultures of Staphylococcus epidermidis
Endpoint domain: Infections and infestations outcomes
Primary endpoint: Number of flatulence events per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Radiographic union at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical healing rates at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Short Musculoskeletal Function Assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: t-PA:Ag levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of levothyroxine formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of exposure under fasting conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: QTcB interval changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5-fluorouracil concentration in cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of painful procedures per patient per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEFS (Lower Extremity Functional Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV risk practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mCPDAI response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L1-4 BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in anxiety sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of sumatriptan, NE, and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of sumatriptan, NE, and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of congenital PCHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral of babies with moderate or severe PCHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False-negative rate of neonatal screening
Endpoint domain: Adverse events/effects
Primary endpoint: Meeting DSPD criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: red blood cell transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of CLAK events leading to termination
Endpoint domain: Adverse events/effects
Primary endpoint: PRA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PGE2 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Social competence skills improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: workability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lower anxiety and depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Higher self-care scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lower final haemoglobin A1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major adverse cardiac and cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of anti-HCV positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success rates for relief of symptomatic epiphora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of dye clearance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyoid bone position angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the plasma drug concentration-time curve (AUC) of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma drug concentration of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of fatal CHD
Endpoint domain: Mortality/survival
Primary endpoint: Expected survival time to a CHD event
Endpoint domain: Mortality/survival
Primary endpoint: lens water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of pictorial warnings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early virologic response (EVR) at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma triglycerides concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased alpha power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle of tilt of intraocular lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decentration of intraocular lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of in‐patient days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Toxicity-associated rehospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: mean percentage change in apoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage change in total IgG apoB-IC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage change in total IgM apoB-IC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of marked lung fibrosis
Endpoint domain: Adverse events/effects
Primary endpoint: PROMIS Physical Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: resection speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total volume per area resected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success rate of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants remaining smoke-free at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Respiratory quotient (RQ) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in hirsutism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glaucomatous progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median visual analogue scale pain score for labour pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in H(2) S levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malodour levels by organoleptic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative hypotension frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Total costs
Endpoint domain: Resource use
Primary endpoint: bleeding time reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding stopped within 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for additional measures to arrest hemorrhage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma levels of Se
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma levels of NOx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of Candida albicans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAS scores at rest and on mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first paracetamol administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child food responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child satiety responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cumulative rate of uveitis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of daily corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative elevation of intraocular pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of SF36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in BDNF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative agitation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSG wake time after sleep onset (WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: hospitalization rate
Endpoint domain: Mortality/survival
Primary endpoint: combined endpoint of mortality or hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of death
Endpoint domain: Mortality/survival
Primary endpoint: Platelet Inhibition Rate (PRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score during lumbar puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provider satisfaction with procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of catheter devices used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Contrast administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fluoroscopy time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Muscle mass improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isometric peak torque improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Eccentric peak torque improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: OH-related symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local and systemic events after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: ChAdV-63-neutralizing titres post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hypertension and/or urine abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: overall abdominal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gray Matter Volume (GMV) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Brain Volume Change (PBVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Volume Variation (LVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleansing efficacy in the right colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of MD expressed in l/min fall in PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mBPI-SF pain intensity and pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RTclin test performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative plasma isofuran concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum conversion at two months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's rating of medication helpfulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relief of local pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in stress score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cumulative morbidity rate
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac mortality from low cardiac output or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Time to attain 25% of total energy expenditure and protein needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to attain 50% of total energy expenditure and protein needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Desensitization to egg allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained unresponsiveness to egg allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cost per quality-adjusted life-year (QALY) gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: earlier return of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes